Fairvalue-Calculator Fairvalue-Calculator
EN DE

Little Green Pharma Ltd (LGP) Fair Value & Analysis

Healthcare · AU · Market cap A$73.0M

PriceA$0.0640
Fair ValueA$0.0678
Upside+6.0%
Quality95/100
Evidence: Medium Range A$0.0550 – A$0.0806

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Little Green Pharma Ltd (LGP) currently trades at A$0.0640, while our model-based Fair Value estimate is A$0.0678 — implying the stock looks roughly 6.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Little Green Pharma Ltd produces and sells cannabis-based medicinal products across Australia and Europe. The company also provides infrastructure to support plant genetics programs and the development of its flower portfolio. It sells its products through a network of wholesalers, pharmacies, clinics, and GPs (general practitioners). The company was founded in 2016 and is based in Wembley, Australia.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Little Green Pharma Ltd (LGP) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0678 versus a price of A$0.0640 — about +6% (undervalued). Model-based estimate, not financial advice.
What is the fair value of LGP?
Our 21-model fair value for Little Green Pharma Ltd is A$0.0678 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0640.
What is the quality score of LGP?
Little Green Pharma Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.